A director at Daehan New Pharmaceuticals bought 100,000 shares at 7,910.000KRW and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
A director at Metemtur Otelcilik Ve Tur sold 850,000 shares at 13.414TRY and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
>Conclusion: Good Q1 net profit, material SBB, stable NII and costs - For Q1 24, we expect a net profit of € 1.52bn with assumed 10bp of loans in loan losses. For Q1 24 we expect a relatively stable net interest income (NII) and expenses. We expect a front loaded SBB announcement of € 3.5bn. For the coming two years we expect continuing wage increases even with a possible slowdown of inflation. The RWA/loan ratio is at an all-time low. Going forward we expect more wa...
>Des résultats au T1 2024 très légèrement au-dessus du consensus (1%) - CA du T1 2024 ressort en hausse de 2,1% à 9 850 M€ (0,9% au-dessus du cons. de 9 758 M€), tiré par la croissance en Afrique. L’EBITDAaL du T1 2024 est en hausse de 2,3% à 2 440 M€ (0,4% au-dessus du consensus de 2 430 M€). Les objectifs 2024 sont confirmés : légère croissance de l’EBITDAaL (+2,4% au T1), investissements disciplinés (+3%), FCF > 3,3 Md€ (pas de publication au T1) et dividende de 0,...
>Q1 2024 results beat expectations by 4% at the operating level and by 13% at the NI with lower taxes - AkerBP just released its Q1 2024 results with 1/ revenues of $ 3,078m, down 13.4% q-o-q and 1% ahead of the consensus. 2/ EBITDA totalled $ 2,787m, down 12.2%, 1.3% below our expectations and 4% ahead of estimates. EBIT came in at $ 2,194m, in line with our expectations and 4% ahead of the consensus. Adjusted net income was robust at $ 531m, up 223% q-o-q and 13% ah...
>Q1 2024 results a shade above the consensus (1%) - Q1 2024 revenues grew 2.1% to € 9,850m (0.9% above the consensus forecast for € 9,758m), driven by growth in Africa. Q1 2024 EBITDAaL grew 2.3% to € 2,440m (0.4% above the consensus at € 2,430m). The 2024 targets are confirmed: low growth in EBITDAaL (+2.4% in Q1), investment discipline (+3%), FCF > € 3.3bn (not published in Q1) and a dividend of € 0.75.The good news: effect of the price increases in Fra...
>Organic volume and revenue growth ahead of expectations in Q1 2024 - Heineken reported net revenue of € 6,847m in Q1 2024, slightly below our forecast of € 6,877m and below consensus of € 6,937m as well. Organic revenue growth was 9.4%, ahead of our forecast of 6.4% and consensus of 7.2%. Consolidated beer volumes were 55.4m hl, slightly below consensus of 55.7m hl and ahead of our forecast of 54.8m hl. Organic beer volume growth was 4.7%, which was clearly ahead of ...
>Q1 2024 results beat expectations by 4% at the operating level and by 13% at the NI with lower taxes - AkerBP just released its Q1 2024 results with 1/ revenues of $ 3,078m, down 13.4% q-o-q and 1% ahead of the consensus. 2/ EBITDA totalled $ 2,787m, down 12.2%, 1.3% below our expectations and 4% ahead of estimates. EBIT came in at $ 2,194m, in line with our expectations and 4% ahead of the consensus. Adjusted net income was robust at $ 531m, up 223% q-o-q and 13% ah...
>CA T1 : 6.8% sur l’organique Core business, 5.5% non ajusté d’un jour travaillé - Eurofins publie un CA T1 de 1 653 M€, en hausse de 5.0% légèrement en dessous de nos estimations (1 717 M€) et de celles du consensus Visible Alpha (1 699 M€). Ajusté d’un jour de travail en moins de c. 1.3%, la croissance organique Core Business est ressortie à 6.8% i.e un niveau légèrement supérieur à la guidance du groupe de 6.5%. en publié, le LFL Core Business ressort à 5.5% (sur...
A director at Danske Bank AS sold 60,000 shares at 208.230DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
A director at WiseTech Global Limited maiden bought 570 shares at 88.590AUD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
>Q1 revenues: 6.8% organic growth in core business, 5.5% not adjusted for a working day - Eurofins reported Q1 revenues of € 1,653m, up 5.0%, slightly below our estimates (€ 1,717m) and Visible Alpha consensus (€ 1,699m). Adjusted by one less working day of around 1.3%, core business organic growth came in at 6.8%, i.e. slightly above the group's guidance of 6.5%. In published figures, core Business LFL growth came in at 5.5% (for Visible Alpha, the figure given was ...
>Q1 sales sharply down and well below our expectations - Haulotte reported yesterday evening its Q1 2024 sales figures. Sales came in sharply down (-19% in organic terms to € 157m), well below our expectations (€ 200m).The quarter was marked by a return to normal in investment cycles and a certain wait-and-see attitude among rental companies, while Q1 2023 had been stimulated by the supply difficulties previously encountered.Europe has been notably suffering...
>Q1 2024 sales: +13.3%: a good organic level - Q1 2024 sales were € 822.4m, +10.9% (+13.3% cc.) with sales in oncology up +7.5% cc, rare diseases +69% cc (although with the entry into the scope of consolidation of Sohonos) and neuroscience at +19.6% cc.Forex had an impact of close to -2.5% in Q1.The group reaffirmed its guidance (growth of 6% cc and an operating margin of around 30%).The main franchises are solid - New products faring well - §sep...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.